Modeling Predicts Effective Approach to HIV Drug Resistance
Modeling Predicts Effective Approach to HIV Drug Resistance
- The options built into the HIV Synthesis Model to confront the resistance to NNRTIs, evidenced particularly with first-line efavirenz (Sustiva, Bristol-Myers Squibb), were based on using dolutegravir (Tivicay, ViiV Healthcare), which is the WHO-recommended alternative to efavirenz-centered regimens.
- The options built into the HIV Synthesis Model to confront the resistance to NNRTIs, evidenced particularly with first-line efavirenz (Sustiva, Bristol-Myers Squibb), were based on using dolutegravir (Tivicay, ViiV Healthcare), which is the WHO-recommended alternative to efavirenz-centered regimens.